| Literature DB >> 20883113 |
Sebastien Crouzet1, Francois J Murat, Gilles Pasticier, Philippe Cassier, Jean Y Chapelon, Albert Gelet.
Abstract
Two devices are currently available for the treatment of prostate cancer with HIFU: Sonablate® and Ablatherm®. The outcomes achieved for primary-care patient are very promissing with mid- and long-term progression-free survival rates around 70%, negative postoperative prostate biopsies almost 85%, and an excellent morbidity profile. Moreover, HIFU has a considerable potential for local recurrence after radiation failure. Recently, some early experiences on focal therapy suggest that HIFU could be an excellent option for highly selected patient.Entities:
Mesh:
Year: 2010 PMID: 20883113 DOI: 10.3109/02656736.2010.498803
Source DB: PubMed Journal: Int J Hyperthermia ISSN: 0265-6736 Impact factor: 3.914